Trial Profile
An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject High and Low Dosage Regimens) Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary) ; Ferrous sulfate
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Acronyms FIND-CKD
- Sponsors Vifor
- 27 Feb 2017 Results of post hoc analysis assessing safety of ferric carboxymaltose versus oral iron over an extended period published in the Nephrology Dialysis Transplantation
- 15 Apr 2014 New trial record
- 11 Nov 2013 Results were presented at the American Society of Nephrology (ASN) Kidney Week in November 2013.